Beijing Tong Ren Tang Chinese Medicine Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Wang Chi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up
Oct 04
Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders
Sep 06Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?
Sep 02Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk
Feb 05Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Jan 03A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Sep 28Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today
Jul 12Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?
Mar 29Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28
Apr 28Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28
Mar 25Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?
Oct 27Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 28Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Mar 11What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Feb 04Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?
Jan 18
Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?
Dec 29Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Dec 11Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 23CEO
Wang Chi (49 yo)
less than a year
Tenure
Mr. Wang Chi is Executive Director and Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited from May 10, 2024. Mr. Chi has experience in Medical and Pharmaceutical industry. Mr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | less than a year | no data | no data | |
| Executive Director & Executive Deputy GM | less than a year | HK$975.00k | 0.0073% HK$ 491.9k | |
| CEO & Executive Director | less than a year | no data | no data | |
| CFO & Company Secretary | 4.5yrs | no data | no data | |
| Deputy GM & General Counsel | no data | no data | no data |
0.7yrs
Average Tenure
50yo
Average Age
Experienced Management: 3613's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | less than a year | no data | no data | |
| Executive Director & Executive Deputy GM | 4.7yrs | HK$975.00k | 0.0073% HK$ 491.9k | |
| CEO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 7.2yrs | HK$288.00k | no data | |
| Independent Non-Executive Director | 11.6yrs | HK$288.00k | no data | |
| Non-Executive Director | 2.3yrs | no data | no data | |
| Independent Non-Executive Director | 1.7yrs | HK$240.00k | no data |
2.3yrs
Average Tenure
53yo
Average Age
Experienced Board: 3613's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.